Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome
Condition: Metabolic Syndrome
MeSH terms: Metabolic Syndrome; Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      In Mexico, obesity is a major public health problem. In recent years he has presented a
      considerable increase in the population. As a result, it has triggered a proportional
      increase in the incidence of cardiovascular disease and the development of Metabolic Syndrome
      (METS). Abdominal obesity is one of the main components of METS which is generally associated
      with insulin resistance / hyperinsulinemia. This is influenced both by the subcutaneous
      adipose tissue as visceral adipose tissue. There is evidence that the visceral fat has an
      important bearing on many factors of METS, like: glucose intolerance, hypertension,
      dyslipidemia, and insulin resistance.

      For management it requires a multidisciplinary approach, including changes in lifestyle,
      psychological and nutritional intervention as well as pharmacological and non-pharmacological
      support.

      Among non-pharmacological therapies, there is recently the use of Conjugated Linoleic Acid
      (ACL) and leucine where in its assigned properties include weight reduction, anti-atherogenic
      , hypocholesterolemic and immunostimulant effect and anticarcinogenic properties. Regarding
      weight reduction dominates the mechanism of action anti-lipolytic effect. But, studies are
      needed to link this consumption with the increase or decrease on visceral fat in individuals
      with METS.
    

Detailed description: 
      The main objective is to compare the effect of the administration of ACL/Leucine vs.
      Metformin on visceral fat area in patients with METS. We will conduct a double-blind trial,
      randomized, on 4 groups, each group with 26 male and female patients of 35-65 years of age
      with METS diagnosed by IDF criteria. Randomization will determine who will receive the
      intervention during 8 week trial, each group will be like:

      Group (A) intervention with ACL/Leucine plus Metformin: 26 individuals will receive
      ACL/Leucine in a dosis of 2,475mg per 24 hrs (1,650mg or 2 capsules with the first meal and
      825 mg or 1 capsule with the second meal) plus Metformin in a dose of 500 mg per day (with
      the first bite of the second meal) during 8 weeks.

      Group (B) Metformin plus Placebo of ACL/Leucine: 26 individuals will receive Metformin in a
      dose of 500 mg per day (with the first bite of the second meal) plus homologue placebo of
      ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg
      with the first meal and 1200 mg or 1 capsule with the second meal) during 8 weeks.

      Group (C) ACL/Leucine plus Metformin's Placebo: 26 individuals will receive ACL/Leucine in a
      dose of 2,475mg per 24 hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule
      with the second meal) plus homologate placebo of metformin (calcined magnesia) in a dose of
      500 mg per day (with the first bite of the second meal) during 8 weeks.

      Group (D) Placebo of ACL/Leucine plus Placebo of Metformin: homologate placebo of ACL/Leucine
      (linseed oil capsules) in a dose of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first
      meal and 1200 mg or 1 capsule with the second meal) plus homologated placebo of metformin
      (calcined magnesia capsules) in a dosis of 500 mg per day (with the first bite of the second
      meal) during 8 weeks.

      The clinical findings and laboratory test include a metabolic profile and biosafety, which
      will be baseline and at 8 weeks.

      Visceral fat area, epicardial fat, body weight, body fat, body mass index (BMI) and blood
      pressure will be determined during the inicial and final visit, likewise, hemodynamics
      parameters of arterial stiffness like aortic pulse wave velocity (PWVao), central pulse
      pressure (PPao), aortic augmentation index (IAxao) and central systolic blood pressure (cSBP)
      by an oscillometric monitoring system via BPLab ®. Adverse events and adherence to treatment
      will be documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is
      considered with significance at p<0.05.
    

Intervention name(s): Conjugated linoleic acid/Leucine; Metformin; Placebo of ACL/Leucine; Placebo of Metformin
Intervention type(s): Dietary Supplement; Drug; Dietary Supplement; Other
Intervention description(s): Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.; Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks; Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.; homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
Other intervention name(s): UKN; Predial plus; Linseed oil; Calcinated magnesia
Intervention MeSH terms: Metformin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Conjugated Linoleic Acid; Leucine; visceral fat area; Epicardial Fat; Hemodinamic Parameters